01.12.2024, 2748 Zeichen

Marinomed: Marinomed Biotech AG has signed an agreement on the sale of its Carragelose business to the French CDMO Unither Pharmaceuticals. The contract provides for upfront and milestone payments in total of up to EUR 20 million, including an upfront payment of up to EUR 5 million. Further payments depend on the achievement of defined commercial and operational targets over the next two years. Closing of the transaction is subject to typical conditions such as merger control, the successful completion of the restructuring proceedings and the approval by the Company's shareholders at an extraordinary general meeting. The agreement provides for the transfer of the entire Carragelose portfolio, including all associated agreements and business relations. As part of the agreement, Marinomed and Unither are also intending to enter into a transition service agreement at completion of such transaction. The proceeds from the sale of the Carragelose business are planned to finance both the operating business, with increased focus on the Marinosolv platform, and the restructuring plan agreed upon with the Company's creditors on November 14, 2024.
Marinomed Biotech: weekly performance: 31.87%

Strabag: STRABAG SE is pursuing entry into the Australian market through acquisition of Georgiou Family Pty, a leading building and civil construction company, and has reached an agreement with the sellers on the main terms of a share deal.  STRABAG plans to acquire 100% of the shares in Perth-based Georgiou, which generates an annual output of around € 790 million, effective retroactively from 30 June 2024. The purchase price, which has yet to be finalised, will be in the low three-digit million euro range. The transaction will be financed through existing cash and cash equivalents.
Strabag: weekly performance: -0.90%

CA Immo: Real estate company CA Immo recorded a 4% increase in rental income in first nine month to €179.1m despite the sale of non-strategic properties. This development is primarily due to higher rental income in the portfolio and the completion of project developments in previous years. Earnings before interest, taxes, depreciation and amortization (EBITDA) stood at €131.0m, 51% below the previous year´s figure (30.09.2023: €268.4m), mainly due to the lower sales result. The revaluation result totaled €–119.2m (30.09.2023: €–155.7m), which corresponds to a decrease of around 2.3% of FY 2023 gross asset value. At €–33.4m, consolidated net result was below the previous year's figure of €61.1m. Earnings per share amounted to €–0.34 on the balance sheet date (€0.62 per share as at 30.09.2023).
CA Immo: weekly performance: 3.92%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (27/11/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1211: ATX fester, starke Andritz überholt Do&Co (war mehr als 1100 Tage vorne) in unserer 25-Jahres-Wertung

Bildnachweis

Aktien auf dem Radar:Rosenbauer, Kapsch TrafficCom, Palfinger, Austriacard Holdings AG, Semperit, CPI Europe AG, VIG, FACC, Emerald Horizon AG, Lenzing, Gurktaler AG VZ, Marinomed Biotech, Rath AG, Verbund, Wolford, Wolftank-Adisa, BKS Bank Stamm, Amag, DO&CO, EuroTeleSites AG, Österreichische Post, Telekom Austria, UBM, Apple, Amazon, Alphabet-A, DAIMLER TRUCK HLD..., Fresenius Medical Care, Deutsche Bank, RWE, Deutsche Telekom.

---